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Introduction {#acn3778-sec-0005}
============

Hereditary transthyretin amyloidosis (ATTR) is an autosomal‐dominantly inherited disorder caused by a mutation in the transthyretin gene (*TTR*), which alters the biochemical property of transthyretin to increase its propensity to be misfolded and lead to formation of pathologic amyloid aggregates. ATTR preferentially manifests with peripheral and autonomic neuropathy, also known as familial amyloidotic polyneuropathy (FAP); however, it may also involve other vital organs.[1](#acn3778-bib-0001){ref-type="ref"}, [2](#acn3778-bib-0002){ref-type="ref"} Cardiac transthyretin amyloidosis, another important phenotype of ATTR, is a devastating cardiomyopathy characterized by concentric ventricular thickening, low cardiac output, atrial dilatation, and disturbed conduction system.[3](#acn3778-bib-0003){ref-type="ref"} Usually, ATTR patients may develop both cardiac and neuropathic phenotypes during their disease courses.[4](#acn3778-bib-0004){ref-type="ref"}

More than 120 *TTR* mutations have been reported worldwide, and there are considerable genotype‐phenotype variations among different ethnic groups.[1](#acn3778-bib-0001){ref-type="ref"} *TTR* Val30Met is the most common variant in the Portugal, Swedish, and Japanese populations,[1](#acn3778-bib-0001){ref-type="ref"} while Val122Ile mutation is endemic in African‐Americans.[5](#acn3778-bib-0005){ref-type="ref"}, [6](#acn3778-bib-0006){ref-type="ref"} Patients harboring *TTR* Val30Met mutation usually present with peripheral neuropathy, but those carrying the Val122Ile mutation commonly manifest with late‐onset cardiomyopathy.[3](#acn3778-bib-0003){ref-type="ref"} *TTR* Thr60Ala, the most common *TTR* mutation in the United Kingdom population, is associated with early cardiac involvement, autonomic dysfunction and peripheral neuropathy of variable severity.[7](#acn3778-bib-0007){ref-type="ref"}, [8](#acn3778-bib-0008){ref-type="ref"} To be noticed, certain *TTR* mutations, such as Leu58His, Ile84Ser, and Tyr114His, are associated with neuropathy starting in the upper limbs as carpal tunnel syndrome (CTS).[1](#acn3778-bib-0001){ref-type="ref"} These findings suggest a broad genetic and phenotypic spectrum in ATTR and stress on the importance of clarifying the ethnic‐specific spectrum of *TTR* mutations and the corresponding phenotype--genotype correlations.

There may be a distinct spectrum of *TTR* mutations in Taiwan. Several small‐scaled studies only identified the Ala97Ser mutations in Taiwanese patients with FAP,[9](#acn3778-bib-0009){ref-type="ref"}, [10](#acn3778-bib-0010){ref-type="ref"}, [11](#acn3778-bib-0011){ref-type="ref"}, [12](#acn3778-bib-0012){ref-type="ref"} and this mutation has never been reported in Caucasian populations. Furthermore, 98% of Taiwanese populations are of Han Chinese descent and there is no large cohort study about ATTR in Chinese populations. Hence, it is intriguing and important to have a comprehensive knowledge of genotypic and phenotypic spectrum of *TTR* mutations in Taiwan, which may help diagnosis and management of ATTR, especially in patients of Chinese descent.

In this study, we characterized the clinical and genetic features of 79 Taiwanese patients with ATTR, including the cardiac manifestations. We also investigated the founder effect of the *TTR* Ala97Ser mutation.

Materials and Methods {#acn3778-sec-0006}
=====================

Subjects {#acn3778-sec-0007}
--------

A consecutive series of 79 individuals with ATTR from 57 pedigrees of Han Chinese descent were recruited from the Neurological Service in Taipei Veterans General Hospital, which is a 2947‐bed national medical center in Taiwan, serving both veterans and regular citizens and accepting difficult neuromuscular disease cases referrals. The diagnosis of ATTR was based on the consensus from the European Network for TTR‐FAP (ATTReuNET).[13](#acn3778-bib-0013){ref-type="ref"} All the 79 participants had peripheral neuropathy with variable motor, sensory, and autonomic symptoms as well as a pathogenic *TTR* mutation. Another two asymptomatic gene carriers with a *TTR* Ala97Ser mutation were enrolled for the cardiac scintigraphic imaging study. The study was approved by the institutional review board of the Taipei Veterans General Hospital, and written informed consent was obtained from all participants.

Clinical evaluation, disability assessment and electrophysiology {#acn3778-sec-0008}
----------------------------------------------------------------

The presence of relevant symptoms and neurological findings were recognized by detailed clinical evaluation, including history taking, medical record review, and physical examination. DN4 questionnaire, consisting of ten items with a total score of 10, was used to assess neuropathic pain with a cut‐off value ≥ 4 points.[14](#acn3778-bib-0014){ref-type="ref"} In addition, the clinical functional status and the severity of disability were evaluated according to the clinical stages of Transthyretin Familial Amyloidotic Polyneuropathy (TTR‐FAP) with a scale of 0 to III (stage 0, no symptoms; stage I, unimpaired ambulation, mostly with mild sensory, motor, and autonomic neuropathy in the lower limbs; stage II, assistance for ambulation required, mostly with a moderate motor, sensory, and autonomic impairment of the four limbs; stage III, wheelchair‐bound or bedridden status with severe sensory, motor, and autonomic involvement of all limbs).[15](#acn3778-bib-0015){ref-type="ref"}

Electrophysiological studies were performed using a Medlec electromyograph. Our patients underwent motor nerve conduction studies in the upper and lower extremities, including median, ulnar, tibial, and peroneal nerves. Ring electrode recordings were carried out to assess sensory conduction of the median, ulnar, and sural nerves. The parameters, including distal latency, nerve conduction velocity, amplitude of compound muscle action potential, amplitude of sensory action potential, and minimal F response, were recorded.

Cardiac evaluation {#acn3778-sec-0009}
------------------

Echocardiography was performed with two‐dimensional and M mode settings. Left ventricular (LV) wall thickening, systolic function, diastolic function, and left atrial (LA) diameter were measured. To evaluate cardiac amyloidosis, the cardiac single photon emission computed tomography with computed tomography (SPECT/CT) and ^99m^Technetium‐pyrophosphate (^99m^Tc‐PYP) scintigraphy were performed after intravenous injection of 15 mCi ^99m^Tc‐PYP for 1 h and 3 h, respectively. Myocardial PYP uptake was rated by semi‐quantitative visual grading with the isotope intensity of rib as reference:[16](#acn3778-bib-0016){ref-type="ref"}, [17](#acn3778-bib-0017){ref-type="ref"} Grade 0: no uptake and normal bone uptake; Grade 1: uptake less than rib uptake; Grade 2: uptake equal to rib uptake; Grade 3: uptake greater than rib uptake with mild or absent rib uptake.

Pathological evaluation {#acn3778-sec-0010}
-----------------------

Pathological diagnosis of amyloidosis was achieved in nine patients, including five with sural nerve biopsies, three with rectal biopsies, and one with bronchoalveolar lavage and bronchoscopic biopsy. Sections from paraffin‐embedded biopsied tissues were stained with hematoxylin‐eosin (H‐E) and Congo red. Optical microscopy with polarized light was used to detect amyloid deposition. The presence of a pathogenic mutation in TTR, a family history, and either a typical clinical manifestation or pathological confirmation in another family member was sufficient for diagnosis of ATTR.

Genetic analysis {#acn3778-sec-0011}
----------------

Genomic DNA was isolated from white blood cells. Mutation analyses were performed by polymerase chain reactions (PCR) amplification using intronic primers and Sanger sequencing. The intronic primers used to amplify all the exons of *TTR* were described previously.[9](#acn3778-bib-0009){ref-type="ref"} All amplicons were sequenced for both sense and antisense strands using the Big Dye 3.1 dideoxy terminator method (Applied Biosystems, Foster City, CA) on an ABI Prism 3700 Genetic Analyzer (Applied Biosystems). Mutations were identified by aligning the amplicon sequences with the published human *TTR* coding sequence (RefSeq NM_000371.3).

Haplotype analysis {#acn3778-sec-0012}
------------------

To investigate whether there is a founder effect for the *TTR* Ala97Ser mutation, the haplotype analysis was performed in fifteen families carrying the mutation. Four polymorphic microsatellite and seven single nucleotide polymorphism (SNP) markers flanking *TTR* and covering a region of 1.5 Mb were genotyped. These markers are D18S49, rs12709651, rs7232282, rs7231553, D18S1242, rs1080093, rs1080094, rs8098191, D18S2021, rs614342, and D18S457. The first seven makers are centromeric and the following four markers are telomeric to *TTR*. All the information regarding these markers were obtained from the Genome Data Viewer (<http://www.ncbi.nlm.nih.gov/genome/gdv/browser/>).

Statistical analysis {#acn3778-sec-0013}
--------------------

The demographic data of the participants were included for descriptive statistics. For inferential statistics, continuous variables were compared between two defined groups using Student\'s t‐test, while categorical variables were compared using Chi‐square test or Fisher\'s exact test where appropriate. A *P*‐value less than 0.05 in a two‐tailed test was considered to be statistically significant.

Results {#acn3778-sec-0014}
=======

Clinical manifestations and electrophysiological findings {#acn3778-sec-0015}
---------------------------------------------------------

The demographic data and clinical features of the 79 ATTR patients are shown in Table [1](#acn3778-tbl-0001){ref-type="table"}. The mean age at onset (AO) was 58.2 ± 7.2 years (range: 40--75 years). The mean disease duration from symptom onset to first neurological evaluation was 4.1 ± 3.6 years (range: 0--13 years). The male participants had a significantly earlier AO than the female patients did (56.6 ± 5.7 vs. 61.8 ± 8.9, *P* = 0.013). The first symptoms usually were sensory abnormalities over bilateral upper limbs as carpal tunnel syndrome (CTS) (43%), asymmetric sensory symptoms presenting as radiculopathy pattern (13.9%), and symmetric sensory‐motor complaints (13.9%). At evaluation, 81% of the patients had sensory‐motor symptoms, and up to 70% had autonomic symptoms. Electrophysiological studies revealed generalized axonal sensorimotor polyneuropathy and isolated median neuropathy in 84.5% and 15.5% of the patients, respectively.[18](#acn3778-bib-0018){ref-type="ref"}, [19](#acn3778-bib-0019){ref-type="ref"} Approximately half of the Taiwanese ATTR patients had severe functional disability at the time of diagnosis, including 36.7% having impaired ambulation (FAP stage II) and another 13.9% being wheel‐chair bound (FAP stage III). Furthermore, 22.8% of them had bulbar dysfunction and 44.3% had more than 5% of body weight loss within 6 months before diagnosis.[20](#acn3778-bib-0020){ref-type="ref"}, [21](#acn3778-bib-0021){ref-type="ref"}

###### 

Demographic data and clinical characterization of ATTR patients in Taiwan

                                                           Mean (SD) or patient number (%)      ATTR patients (*n* = 79)
  -------------------------------------------------------- ------------------------------------ --------------------------
  Demographics                                             Male                                 55 (69.6%)
  Family History                                           63 (79.7%)                           
  Age at onset (y)                                         58.2 (7.2)                           
  Age at evaluation (y)                                    62.3 (7.2)                           
  First symptoms[1](#acn3778-note-0002){ref-type="fn"}     Sensory symptoms of ULs              34 (43%)
  Sensory, asymmetry                                       11 (13.9%)                           
  Sensory‐motor                                            11 (13.9%)                           
  Sensory, symmetry                                        9 (11.4%)                            
  Motor                                                    5 (6.3%)                             
  Heart                                                    4 (5.1%)                             
  Autonomic symptoms                                       4 (5.1%)                             
  Generalized                                              1 (1.3%)                             
  Presentation at evaluation                               Sensory‐motor                        64 (81.0%)
  Autonomic dysfunction                                    55 (69.6%)                           
  Neuropathic pain (DN4)                                   48 (60.8%)                           
  Body weight loss                                         35 (44.3%)                           
  Heart                                                    24 (30.4%)                           
  Heart failure                                            15 (19.0%)                           
  Cardiac arrhythmia                                       11 (13.9%)                           
  Bulbar symptoms                                          18 (22.8%)                           
  Sensory                                                  13 (16.5%)                           
  Motor                                                    2 (2.5%)                             
  Clinical severity (FAP stage)                            Stage I                              39 (49.4%)
  Stage II                                                 29 (36.7%)                           
  Stage III                                                11 (13.9%)                           
  Electrophysiology                                                                             (*n* = 71)
                                                           Isolated median neuropathy           11 (15.5%)
                                                           Axonal sensorimotor polyneuropathy   60 (84.5%)
  Echocardiography[2](#acn3778-note-0003){ref-type="fn"}                                        (*n* = 38)
                                                           EF (%)                               54.0%
                                                           LV thickness IVS/PW (mm)             14.1/13.0
                                                           Abnormal Echocardiography (*n*,%)    28 (73.7%)

Sensory symptoms of ULs: symmetrically distal sensory symptoms of upper limbs as carpal tunnel syndrome; Sensory, asymmetry: asymmetric sensory symptoms of upper or lower limbs, referred as a radiculopathy pattern; Sensory‐motor: symmetrically distal sensory‐motor symptoms of four limbs; Motor: exclusive weakness or clumsiness involving upper or lower limbs; Autonomic symptoms: one of related symptoms including orthostatic intolerance, gastrointestinal symptoms (diarrhea, constipation, or alternative symptoms), urinary bladder dysfunction (dysuria and catheterization), impotence, hypohidrosis or anhidrosis; Generalized: symmetric sensory‐motor complaints and autonomic symptoms.

EF, left ventricular ejection fraction; IVS/PW, interventricular septal thickness/posterior wall thickness.
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Conventional cardiac evaluation and cardiac scintigraphic imaging {#acn3778-sec-0016}
-----------------------------------------------------------------

Only 5.1% of the ATTR patients reported cardiac symptoms as their first manifestations. However, up to 30% of all patients had heart failure or cardiac arrhythmia at the time of diagnosis (Table [1](#acn3778-tbl-0001){ref-type="table"}). Thirty‐eight participants underwent echocardiography, and cardiac involvement was found in 73.7% of them with the findings of concentric left ventricular hypertrophy (CLVH), asymmetric septal hypertrophy, granular sparkling appearance of myocardium or systolic dysfunction.

Sixteen patients with ATTR and two asymptomatic gene carriers with a *TTR* Ala97Ser mutation received ^99m^Tc‐PYP scintigraphy. We categorized these participants into three groups according to the presence of neuropathy and cardiac symptoms. Group 1 included three patients with neuropathy and class 2 or more severe heart failure defined by New York Heart Association Functional Classification (NYHA Fc) (ATTR with HF). Group 2 contained 13 ATTR patients with neuropathy but no clinically evident heart failure. Group 3 consisted of two asymptomatic carriers. Their clinical information, neuropathy pattern and scintigraphic grading were demonstrated (Table [2](#acn3778-tbl-0002){ref-type="table"}). The clinical severity between the ATTR patients with or without heart failure was similar in their FAP staging. Significant amyloid deposition was identified in all the patients with heart failure and in 76.9% of patients without clinically evident heart failure. The two asymptomatic gene carriers both had an intermediate degree of cardiac amyloid deposition on ^99m^Tc‐PYP scan. Furthermore, there was no significant association between the pattern of peripheral nerve involvement and severity of cardiac amyloid deposition.

###### 

Clinical information of the individuals receiving scintigraphic analysis of cardiac involvement

                                ATTR with HF   ATTR without HF   Asymptomatic carriers
  ----------------------------- -------------- ----------------- -----------------------
  Male (%)                      2 (66.7%)      9 (69.2%)         0
  FAP stage                                                      
  Stage 1                       2 (66.7%)      9 (69.2%)         0
  Stage 2 & 3                   1 (33.3%)      4 (30.8%)         0
  PYP scan                                                       
  Intermediate (Grade 1)        0 (0%)         3 (23.1%)         2 (100%)
  Significant (Grade 2 & 3)     3 (100%)       10 (76.9%)        0
  Peripheral neuropathy                                          
  Isolated median neuropathy    1 (33.3%)      5 (38.5%)         0
  Sensorimotor polyneuropathy   2 (66.7%)      8 (61.5%)         0

HF, Heart failure defined by New York Heart Association Functional Classification (NYHA Fc) class 2 or more; ATTR, transthyretin amyloidosis; FAP, familial amyloidotic polyneuropathy; PYP scan, ^99m^Technetium‐pyrophosphate (^99m^Tc‐PYP) scintigraphy.

John Wiley & Sons, Ltd

Mutational analysis of Taiwanese ATTR patients {#acn3778-sec-0017}
----------------------------------------------

Mutation analysis of the 57 Taiwanese ATTR pedigrees revealed six missense *TTR* mutations*,* including Ala45Thr (c.193G\>A), Thr60Ala (c.238A\>G), Ile73Val (c.277A\>G), Ser77Try (c.290C\>A), Glu89Asp (c.327G\>T), and Ala97Ser (c.349G\>T) (Fig. [1](#acn3778-fig-0001){ref-type="fig"}A). All the six mutations were present with a heterozygous form. The Glu89Asp mutation was novel, and the other five mutations had been reported as pathogenic mutations before.[8](#acn3778-bib-0008){ref-type="ref"}, [22](#acn3778-bib-0022){ref-type="ref"}, [23](#acn3778-bib-0023){ref-type="ref"}, [24](#acn3778-bib-0024){ref-type="ref"}, [25](#acn3778-bib-0025){ref-type="ref"} The Ala97Ser mutation was the most common mutation in this ATTR cohort, accounting for 52 of the 57 ATTR pedigrees (91.2%). The pedigrees harboring the other five *TTR* mutations were demonstrated in Fig. [1](#acn3778-fig-0001){ref-type="fig"}B. The clinical characteristics of patients with different TTR mutations were shown in Table [3](#acn3778-tbl-0003){ref-type="table"}.

![Pedigrees and electropherograms of the *TTR* mutations in this study. (A) The six *TTR* mutations identified in this study, with the sense strand electropherogram shown on the top and a limited reading frame depicting the corresponding amino acid substitutions shown below. (B) The pedigrees of the patients carrying the *TTR* mutations, including the Ala45Thr, Thr60Ala, Ile73Val, Ser77Tyr, and Glu89Asp mutations. The arrows indicate the probands. The squares and circles denote males and females, respectively. The filled and open symbols represent affected and unaffected members. Dotted symbols represent asymptomatic carriers. Slashed indicate deceased individuals.](ACN3-6-913-g001){#acn3778-fig-0001}

###### 

Phenotype‐genotype characterization of individual patients with different *TTR* mutations

                               Mean (SD); %                               Ala45Thr (*n* = 1)   Thr60Ala (*n* = 1)                Ile73Val (*n* = 2)   Ser77Try (*n* = 1)   Glu89Asp (*n* = 1)              Ala97Ser (*n* = 73)
  ---------------------------- ------------------------------------------ -------------------- --------------------------------- -------------------- -------------------- ------------------------------- ---------------------
  Demographics                 Age at onset                               59                   59                                52 (1.4)             54                   59                              58.3 (7.4)
  Symptom duration (years)     9                                          2                    1.5 (2.1)                         10                   6                    4(3.6)                          
  First symptoms               HF[1](#acn3778-note-0005){ref-type="fn"}   HF                   Sensory UL; Sensory‐motor         Sensory UL           Sensory              Sensory UL (43.8%)              
  Presentation at evaluation   Neuropathy                                 S‐M poly             S‐M poly                          S‐M poly; CTS        S‐M poly             S‐M poly                        S‐M poly (80.8%)
  Autonomic symptoms           OI, GI, UB                                 OI, UB, Vasomotor    GI, UB, Sweat                     GI, UB, Sex          OI, UB, Sex, Sweat   68.5%                           
  Clinical severity            FAP stage 2                                FAP stage 2          FAP stage 2 & 1                   FAP stage 2          FAP stage 2          FAP (2 + 3) 48%                 
  Neuropathic Pain             100%                                       100%                 50%                               100%                 100%                 58.9%                           
  Heart                        HF, Arrhythmia                             HF, Arrhythmia       HF/NR                             NR                   HF                   HF (16.4%) Arrhythmia (15.1%)   
  Echocardiogram               Ejection fraction                          49%                  33%                               43%; 63%             --                   50%                             55.2%
  IVS/PW (mm)                  19/13                                      14/14                20/17; 10/10                      --                   12/11                14/12.9                         
  Nerve conduction study       Axonal S‐M poly.                           Axonal poly.         Axonal poly.; Median neuropathy   Axonal poly.         Axonal poly.         Axonal poly.(84.6%)             

HF: heart failure; Sensory UL: sensory symptoms of upper limbs; S‐M poly: sensorimotor polyneuropathy; OI: orthostatic intolerance; GI: gastrointestinal symptoms (diarrhea, constipation or alternative symptoms); UB: urinary bladder dysfunction (dysuria and catheterization); Sex: impotence; Sweat: hypohidrosis or anhidrosis; Vasomotor: skin color change; FAP stage: stages of Transthyretin Familial Amyloidotic Polyneuropathy; NR: not reported; nl.:normal; EF: ejection fraction; CLVH: concentric left ventricular hypertrophy

Axonal poly.: axonal sensory‐motor polyneuropathy; CTS: carpal tunnel syndrome
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Several lines of evidence support the pathogenicity of the *TTR* Glu89Asp mutation. First, the mutation is not present in the 125,748 exome, and 15,708 whole‐genome sequences from unrelated individuals in the Genome Aggregation Database (gnomAD) as well as the genome data of 1517 Taiwanese controls from Taiwan biobank database (<http://taiwanview.twbiobank.org.tw/index>). Second, two different mutations at the same Glu89 amino acid residue, including Glu89Gln and Glu89Lys, had been identified as pathogenic mutations for ATTR.[26](#acn3778-bib-0026){ref-type="ref"}, [27](#acn3778-bib-0027){ref-type="ref"} Third, two of the three popular bioinformatics tools for predicting the pathogenicity of nucleotide variants support the pathogenic role of *TTR* Glu89Asp. MutationTaster (<http://www.mutationtaster.org>) and PolyPhen‐2 (<http://genetics.bwh.harvard.edu/pph2>) predicted *TTR* Glu89Asp as a disease‐causing variant, whereas SIFT (<https://sift.bii.a-star.edu.sg>) predicted it as a tolerated one. Fourth, the patient with the Glu89Asp mutation has a typical phenotype and pathological finding of ATTR, which is highly specific for *TTR* mutations. Therefore, *TTR* Glu89Asp is classified as a likely pathogenic variant according to the American College of Medical Genetics and Genomics (ACMG) guideline.[28](#acn3778-bib-0028){ref-type="ref"}

Clinical information of the patient carrying the *TTR* Glu89Asp mutation {#acn3778-sec-0018}
------------------------------------------------------------------------

The patient with the *TTR* Glu89Asp mutation presented with distal paresthesia since age 59 years and intermittent chest tightness, diarrhea, and erectile dysfunction since age 64. Progressively ascending numbness, tingling pain and weakness of four limbs accompanying with loss of body weight up to 12 kg developed in the following 2 years. He was wheelchair‐bound by age 68. The neurological examination at age 66 revealed severe hypophonia, generalized areflexia, weakness and muscle wasting and impaired sensation of all modalities in the distal four limbs. The nerve conduction study showed severe axonal polyneuropathy (Table [S1](#acn3778-sup-0001){ref-type="supplementary-material"}). The sympathetic skin responses (SSR) were absent over lower limbs and diminished with prolonged latencies over upper limbs. The heart rate variability test revealed decreased variability on R‐R intervals. Severe postural hypotension (54/27 mmHg at 3rd minutes on standing) was demonstrated by head‐up tilt test. Rectal biopsy of the patient revealed characteristic apple‐green birefringence of amyloid deposits in the Congo red stain (Fig. [2](#acn3778-fig-0002){ref-type="fig"}A and B). The serum and urine protein electrophoresis with immunofixation did not find monoclonal band and the serum free light chain ratio analysis revealed normal values. The echocardiography showed preserved ejection fraction with mild CLVH at age 66 and mild systolic dysfunction at age 69. ^99m^Tc‐PYP scintigraphy and SPECT/CT imaging showed prominent amyloid deposition with visual score of grade 3, mainly locating in the left ventricle, at age 69 (Fig [2](#acn3778-fig-0002){ref-type="fig"}C and D).

![Rectal biopsy and the 99mTc‐PYP scintigraphy and SPECT/CT imaging of the patient with the novel *TTR* Glu89Asp mutation. (A) Pathological sections with the Congo red stain showed an amorphous, small focus of amyloid deposition in submucosa of rectum. (B) Under polarized light examination, the amyloid deposition showed apple‐green birefringence. (C) ^99m^Technetium‐pyrophosphate (^99m^Tc‐PYP) scintigraphy reveals increased PYP uptake in the heart with visual score of grade 3. (D) The SPECT/CT image shows the amyloid deposition mainly located in the left ventricle. Bars = 100 *μ*m.](ACN3-6-913-g002){#acn3778-fig-0002}

Founder Effect of *TTR* Ala97Ser in Taiwan {#acn3778-sec-0019}
------------------------------------------

Haplotype analysis was performed in 91 individuals from 15 pedigrees harboring the p.Ala97Ser mutation, including 47 patients, ten asymptomatic carriers and 34 unaffected subjects. The families were denoted as A to P (Fig. [3](#acn3778-fig-0003){ref-type="fig"}). These families shared a common haplotype covering a region of 0.48 Mb containing loci rs12709651, rs7232282, rs7231553, D18S1242, rs1080093, rs1080094, rs8098191, D18S2021, and rs614342 linked to *TTR* Ala97Ser (C‐C‐A‐1‐C‐A‐mutation‐G‐1‐C), suggesting the presence of a founder effect for the Ala97Ser mutation.

![Haplotype analysis. Haplotype analysis of the microsatellite and single nucleotide polymorphism (SNP) markers flanking the *TTR* gene in 15 ATTR pedigrees (A--P) carrying the *TTR* Ala97Ser mutation. The squares and circles denote males and females. The filled and open symbols represent affected and unaffected members. Dotted symbols indicate asymptomatic gene carriers and the numbers in diamonds are the numbers of unaffected individuals. A slash represents deceased members. The gender and birth order have been partially hidden because of confidentiality.](ACN3-6-913-g003){#acn3778-fig-0003}

Discussion {#acn3778-sec-0020}
==========

The present study comprehensively investigates the clinical features and mutational spectrum of a cohort of 79 patients with ATTR from 57 pedigrees of Han Chinese descent in Taiwan. The studied cohort is the largest ATTR cohort in Han Chinese populations. There are several intriguing findings in this study. Firstly, *TTR* Ala97Ser mutation is the most common cause of ATTR in Taiwan, accounting for 91.2% of the pedigrees. The patients with the Ala97Ser mutation usually present with a late‐onset peripheral neuropathy and autonomic dysfunction at their late fifties, and approximately half of them have CTS as the initial presentation. Upon the time of diagnosis, majority of them had significant cardiac amyloid deposition and abnormal cardiac echocardiographic findings despite less than one‐third of patients report heart symptoms. Secondly, *TTR* Glu89Asp is a novel pathogenic mutation for ATTR. Furthermore, there is a founder effect for the Ala97Ser mutation in Taiwan. Moreover, there was no correlation between the pattern or severity of neuropathy and the severity of cardiac amyloidosis in the ATTR cohort. Cardiac evaluation is mandatory in every patient with ATTR, even in those with very early‐stage disease and trivial symptom.

Taiwanese ATTR population is particular because of the *TTR* Ala97Ser mutation, which contributes to the majority of ATTR in Taiwan but is absent in other populations. Several other population‐specific *TTR* mutations have also been identified.[7](#acn3778-bib-0007){ref-type="ref"}, [8](#acn3778-bib-0008){ref-type="ref"}, [22](#acn3778-bib-0022){ref-type="ref"}, [25](#acn3778-bib-0025){ref-type="ref"}, [29](#acn3778-bib-0029){ref-type="ref"} For example, the Thr60Ala mutation, which is prevalent in British patients with ATTR, is associated with early cardiac and autonomic symptoms and variable severity of peripheral neuropathy in advanced disease stage.[7](#acn3778-bib-0007){ref-type="ref"}, [8](#acn3778-bib-0008){ref-type="ref"}

In addition to the Ala97Ser mutation, five other *TTR* mutations were identified in the Taiwanese ATTR cohort, including the novel Glu89Asp mutation, manifesting as late‐onset neuropathy with obvious autonomic and cardiac involvement. Our work also demonstrated a common haplotype consisting of nine neighboring loci of the microsatellite or SNP markers linked to the *TTR* Ala97Ser mutation in the 15 ATTR families. These findings suggest that the Taiwanese patients harboring the Ala97Ser mutation may be descendants from a common ancestor. A founder effect for the *TTR* Val30Met mutation has also been shown in the Japanese, Swedish and Portuguese populations.[30](#acn3778-bib-0030){ref-type="ref"}, [31](#acn3778-bib-0031){ref-type="ref"} The late disease onset of the Ala97Ser mutation‐associated ATTR makes it easy to inherit the mutation from patients to their offspring.

Our study underlines the importance of cardiac evaluation in every patient with ATTR, even in those without heart symptoms. In the Taiwanese ATTR cohort, less than one‐third of the patients had cardiac symptoms, but near three‐fourths of the ATTR patients receiving echocardiography had abnormal findings. Furthermore, ^99m^Tc‐PYP scintigraphy revealed significant cardiac amyloid deposition in 76.9% of ATTR patients without an overt heart failure symptom. Even for the two asymptomatic *TTR* mutation carriers, an intermediate degree of cardiac amyloidosis was detected by ^99m^Tc‐PYP imaging in both of them. To be noticed, there was no correlation between the pattern or severity of neuropathy and the severity of cardiac amyloidosis in the Taiwanese ATTR cohort. Similar findings were also found in an ATTR cohort in US. Within this cohort, 10 of the 12 (84%) asymptomatic *TTR* mutation carriers had cardiac amyloidosis revealed by ^99m^Tc‐PYP scintigraphy.[32](#acn3778-bib-0032){ref-type="ref"} Since newly emerging RNA interference and antisense oligonucleotide therapies have changed the therapeutic paradigm for ATTR,[33](#acn3778-bib-0033){ref-type="ref"}, [34](#acn3778-bib-0034){ref-type="ref"} routinely genetic testing for *TTR* mutations in individuals at risk and aggressively monitoring cardiac amyloidosis in asymptomatic *TTR* mutation carriers may allow early intervention.[35](#acn3778-bib-0035){ref-type="ref"}

In conclusion, we demonstrated the distinct clinical and genetic profiles of ATTR in Taiwan, where *TTR* Ala97Ser accounts for approximately 90% of ATTR and is associated with a late‐onset neuropathy with autonomic and cardiac involvement. There is a founder effect for the Ala97Ser mutation in Taiwan. One novel mutation for ATTR, Glu89Asp, was identified. Cardiac evaluation is important in ATTR patients, even in those without heart symptoms. These findings provide useful information for the diagnosis and management of ATTR, especially in patients of Chinese descent.
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**Table S1**. Serial clinical information of the patient with the *TTR* Glu89Asp mutation was demonstrated in the supplementary table, including nerve conduction study, echocardiography, and cardiac scintigraphy at the age of 66 and 69.

###### 

Click here for additional data file.
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